Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.

CONCLUSION: This population-based analysis of patients with VTE extends results of randomized clinical trials indicating lower risks of development of recurrent VTE and major bleeding events with use of apixaban versus warfarin in real-world settings. The observed benefits of apixaban extended to selected subgroups of the VTE population, including patients with provoked VTE.
PMID: 31974557 [PubMed - in process]

Source: American Journal of Health-System Pharmacy : AJHP - January 23, 2020 Category: Drugs & Pharmacology Authors: Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic WH, Park H Tags: Am J Health Syst Pharm Source Type: research